| Aug 19 |
Gilead partners with PANTHERx for LIVDELZI distribution
|
| Aug 17 |
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
|
| Aug 15 |
Gilead’s PBC therapy Livdelzi bags accelerated approval
|
| Aug 15 |
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
|
| Aug 15 |
FDA clears Gilead drug acquired in $4.3B buyout
|
| Aug 14 |
Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD)
|
| Aug 14 |
Gilead wins FDA nod for liver disease drug
|
| Aug 14 |
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
|
| Aug 14 |
7 Defensive Stocks to Buy as Investors Seek Shelter
|
| Aug 13 |
Gilead Sciences Second Quarter 2024 Earnings: Beats Expectations
|
